-
- ADME/DMPKDrug Efficacy Testing
- Cerebral Infarct Size Measurement
- Histological Assessment
- Physiological Monitoring
- Behavioral TestingBrain Imaging
- Cerebral Blood Flow Monitoring
- Brain Edema Measurement
- Assessment of Blood-Brain Barrier
- Assessment of Leukocyte-Platelet Aggregates
- Quantitative Analysis of Protein and mRNA Expression
Safety AssessmentIn Vitro Pharmacology- Cell Viability Assay
- Caspase-3 Activity Assay
- In Vitro Neuroinflammatory Models and Assays
- Excitotoxicity In Vitro Assay
- Cell-Based Mitochondrial Function Assay
- In Vitro Oxidative Stress Assay
- Ischemia-Triggered Glutamate Excitotoxicity
- NMDA Receptor-mediated Excitotoxicity
- AMPA Receptor-mediated Excitotoxicity
Molecular Mechanism of Oxidative StressNeuroinflammatory Mechanisms- Ischemia-Reperfusion Injury
Cell Death Mechanism- Autophagy MechanismApoptotic Mechanism
- Ferroptosis Pathways
- Necroptosis Signaling Pathways
Epigenetic Mechanism- Gut Microbiota
- Animal Modeling of Stroke
- Animal Modeling of Ischemic StrokeAnimal Modeling of Hemorrhagic StrokeIn Vitro Modeling of Stroke
- In Vitro Modeling of Ischemic Stroke
- In Vitro Modeling of Hemorrhagic Stroke
- Small-Molecule Antiplatelet DrugsNeuroprotective PeptidesMonoclonal Antibodies for StrokeStem Cell-Based Therapies for StrokeDrug Delivery SystemsInquiry
Therapeutic Antibody Development for Stroke
Antibody drugs for the treatment of stroke have attracted considerable attention from the scientific community. There is growing evidence that targeting endogenous molecules or signaling cascades with monoclonal antibodies can reduce the severity of injury or completely heal damaged brain tissue. Antibody-based therapies offer a novel adjunct to stroke treatment. Many molecules have been targeted for stroke therapy and many antibodies have been developed. These molecules are primarily located on cell membranes or in the extracellular space, where they can be targeted by antibodies.
Fig. 1. Schematic representative diagram demonstrating intravenous or subcutaneous injection of different forms of antibody-based medications to a stroke patient. (Sun et al., 2022)Our Therapeutic Antibody Development Services
As a CRO service provider focused on stroke, Ace Therapeutics helps clients develop safe and effective therapeutic antibodies. Our comprehensive services cover the full spectrum of therapeutic antibody development, from initial target identification and antibody discovery to preclinical evaluation.
Using our extensive expertise in hybridoma technology, phage display and single-cell sequencing, we help clients to generate a broad range of high-affinity, specific antibodies that selectively modulate key molecular pathways involved in stroke pathogenesis.
Types of Therapeutic Antibodies We Can Develop
Ace Therapeutics identifies and validates multiple molecules as targets and provides one-stop therapeutic antibody development services for stroke.
- Antibodies targeting myelin-associated proteins
- Antibodies targeting the GluN1 subunit of the NMDAR
- Antibodies targeting cell adhesion molecules and cytokines
Improving the Efficacy of Therapeutic Antibodies
Strategies Service Details Custom Antibody Engineering Our skilled engineers use advanced techniques such as Fc engineering and antibody humanization to fine-tune the structural and functional characteristics of therapeutic antibodies. We can extend their half-life, improve BBB permeability, and enhance their ability to trigger desired biological responses in the ischemic brain microenvironment. Cell Receptor-mediated Strategies We make antibodies reach the brain using cellular receptor-mediated strategies. This strategy utilizes certain BBB enriched receptors, such as transferrin receptor (TfR), insulin receptor (IR), and diphtheria toxin receptor (DTR), which can be potentially conjugated to increase the ability of receptor-mediated transport of antibodies into the brain. Antibody-Drug Conjugates We modify the surface of drug-carrying nanoparticles by binding them to brain-specific antibodies. These antibody-drug conjugates recognize specific ligands and act as stroke therapeutics through receptor-mediated endocytosis across the BBB. Single-domain Antibodies We develop single-domain antibodies to be used as carriers for the transport of antibodies across the BBB. In addition, we develop therapeutic single-domain antibodies that improve the BBB and tissue permeability and contribute to surface modifications for site-specific targeting. Why Choose Us
- We have a thorough understanding of the multiple signaling pathways following stroke injury to help clients rationally plan immunotherapy targets and intervention points. Our experts work closely with our clients to carefully design and evaluate animal experiments to fully understand possible side effects following immunotherapy.
- We offer stroke immunotherapy studies, including active immunization with peptide inoculation and passive immunization with direct injection of antibodies into animals.
- We have well-established animal models of stroke to study the efficacy and safety of targeted antibodies to maximize the therapeutic effect of monoclonal antibodies. We also support the study of the therapeutic effects of multiple antibody combinations.
- We offer multiple strategies to enhance BBB permeability to improve antibody-based therapy in the brain.
Ace Therapeutics aims to help clients accelerate the development of therapeutic antibodies for stroke. Our team collaborates with academic and pharmaceutical partners to design and execute well-controlled preclinical studies. Please fell free to contact us. We look forward to working with you!
Reference- Sun, J. M., et al. (2022). Advances in antibody-based therapeutics for cerebral ischemia. Pharmaceutics, 15(1), 145.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket